What is CTOR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.08B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CTOR?

P/E (TTM) is n/a and 52-week range is $0.49 to $2.25 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CTOR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CTOR?

The company profile lists revenue (TTM) near $6M, net income (TTM) near $-44M, EPS (TTM) near $-0.48 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Citius Oncology Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cranford, New Jersey, US, 93M shares outstanding, ISIN US17331Y1091 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Citius Oncology Inc

$CTOR

Health Care · Biotechnology

Run Scenarios

$0.84

+0.57%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. The company is headquartered in Cranford, New Jersey. The company went IPO on 2022-10-14. The firm is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. The company is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

Website

citiusonc.com/

IPO

2022-10-14

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)